Tumor rejection antigens

Details Tumor rejection antigens Tumor rejection antigens

1999-11-26

2009-06-16

Helms, Larry R. (Department: 1642)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S185100, C530S300000

Reexamination Certificate

active

07547439

ABSTRACT:
Polypeptides comprising an unbroken sequence of amino acids from SEQ ID NO: 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.

REFERENCES:
patent: 5686068 (1997-11-01), Boon-Falleur et al.
patent: 5912143 (1999-06-01), Bandman et al.
patent: 6682731 (2004-01-01), Townsend et al.
patent: WO 92/20356 (1992-11-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 95/25530 (1995-09-01), None
patent: WO/9525740 (1995-09-01), None
patent: WO 98/14463 (1998-04-01), None
patent: WO 99/45954 (1999-09-01), None
patent: WO 99/54738 (1999-10-01), None
patent: WO 99/61916 (1999-12-01), None
Kirkin et al, APMIS, 1998, 106: 665-679.
Bowie et al (Science, 1990, 257:1306-1310).
Visseren et al, 1997, Intl J Cancer, 73(1): 125-30.
Stites et al, 1997, Medical Immunology, 9th ed, Appleton & Lange, Stamford, Connecticut, figure 3-9 on p. 51, pp. 50-51, 118-119, 130.
Herbert et al. (The Dictionary of Immunology, Academic Press, 4th edition, 1995, p. 58.
Greenspan et al., Nature Biotechnology 7:936-937 (1999).
Yokota, J et al (Oncogene, 1988,vol. 3, pp. 471-475).
Zimmer (Cell Motility and the Cytoskeleton, 1991, vol. 20, pp. 325-337).
Hell et al (Laboratory Investigation, 1995, vol. 73, pp. 492-496).
Guo et al (Journal of Pharmacology and Experimental Therapeutics, 2002, vol. 300, pp. 206-212).
White et al, 2001, Ann Rev Med, 52: 125-145.
Smith RT, 1994, Clin Immunol, 41(4): 841-849.
Drexler et al (Leukemia and Lymphoma, 1993, 9:1-25).
Embleton et al (Immunol Ser, 1984, 23:181-207).
Hsu (in Tissue Culture Methods and Applications, Kruse and Patterson, Eds, 1973, Academic Press, NY, see abstract, p. 764).
Tian, J et al, 2004, Physiol Genomics, 17: 170-182.
Van Dyke D L et al, 2003, Cancer Genetics and Cytogenetics 241: 137-141.
Zaslav A L et al, 2002, Amer J Medical Genetics 107: 174-176.
Kunkel, P, et al, 2001, Neuro-oncology 3(2): 82-88.
MPSRCH search report, 2006, us-09-856-812b-1.olig.rai, pp. 1-2.
MPSRCH search report, 2006, us-09-856-812b-1—copy—254-262.olig.rai, pp. 1-2.
MPSRCH search report, 2006, us-09-856-812b-1.olig—sz9.rai, p. 3.
Registry No. 53665-55-7, and Search report, 2006, pp. 1-2.
MPSRCH search result, 2007, us.09.856.812.1.oligo-sz9.Rag,result 3, pp. 1-2.
MPSRCH search result, 2007, us.09.856.812b.48.rag, pp. 1-2.
Bergmann et al, 1994 (J Virol, 68(8): 5306-5310).
Eisenlohr et al, 1992 (J Exp Med, 175: 481-487).
Shastri et al, 1995 (J Immunol, 155: 4339-4346).
Guo et al, 1992 (Nature, 360: 364-366).
Chen, Yao-Tseng et al., “Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library,”Proc. Natl. Acad. Sci. USAJun. 1998; 95:6919-6923.
Coulie, P.G., “Antigens Recognized on Human Tumors by Cytolytic T Lymphocytes: Towards Vaccination?”Stem Cells1995; 13(4):393-403.
Dabovic, B. et al., “A family of rapidly evolving genes from the sex reversal critical region in Xp21,”Mammalian genome1995; 6:571-580.
De Plaen, Etienne et al., “Structure, chromosomal localization, and expression of 12 genes of the MAGE family,”Immunogenetics1994; 40:360-369.
Gaugler, Beatrice et al., “Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes,”J. Exp. Med.1994; 179:921-930.
Gilbert, Sarah C. et al., “A protein particle vaccine containing multiple malaria epitopes,”Nature BiotechnologyNov. 1997; 15:1280-1284.
Haas, Gilbert G. et al., “Distribution of Human Leukocyte Antigen-ABC and -D/DR Antigens in the Unfixed Human Testis,”American Journal of Reproductive Immunology and Microbiology1988; 18:47-51.
Hu, Xueyou et al., “Enhancements of Cytolytic T Lymphocyte Precursor Frequency in Melanoma Patients following Immunization with the MAGE-1 Peptide Loaded Antigen Presenting Cell-based Vaccine,”Cancer ResearchJun. 1, 1996; 56:2479-2483.
Huang, Lan-Qing et al., “Cytolytic T Lymphocytes Recognize an Antigen Encoded by MAGE-A10 on a Human Melanoma,”The Journal of Immunology1999; 162:6849-6854.
Lucas, Sophie et al., “Identification of a New Mage Gene with Tumor-specific Expression by Representational Difference Analysis,”Cancer ResearchFeb. 15, 1998; 58:743-752.
Lurquin, Christophe et al., “Two Members of the Human MAGEB Gene Family Located in Xp21.3 Are Expressed in Tumors of Various Histological Origins,”Genomics1997; 46:397-408.
Marchand et al., “Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3,”Int. J. Cancer1995; 63:883-885.
Mukherji, Bijay et al., “Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells,”Proc. Natl. Acad. Sci. USAAug. 1995; 92:8078-8082.
Muscatelli, F. et al., “Isolation and characterization of a MAGE gene family in the Xp21.3 region,”Proc. Natl. Acad. Sci. USAMay 1995; 92:4987-4991.
Nestle, Frank O. et al., “Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells,”Nature MedicineMar. 1998; 4(3):328-332.
Rammensee, Hans-Georg et al., “MHC ligands and peptide motifs: first listing,”Immunogenetics1995; 41:178-228.
Rimoldi, Donata et al., “cDNA and Protein Characterization of Human MAGE-10,”Int. J. Cancer1999; 82:901-907.
Tam, James P. et al., “Incorporation of T and B Epitopes of the Circumsporozoite Protein in a Chemically Defined Synthetic Vaccine Against Malaria,”J. Exp. Med.Jan. 1990; 171:299-306.
Thomson, Scott A. et al., “Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: Implications for vaccine design,”Proc. Natl. Acad. Sci. USAJun. 1995; 92:5845-5849.
Traversari, Catia et al., “A Nonapeptide Encoded by Human Gene MAGE-1 Is Recognized on HLA-A1 by Cytolytic T Lymphocytes Directed against Tumor Antigen MZ2-E,”J. Exp. Med.Nov. 1992; 176:1453-1457.
Uyttenhove, Catherine et al., “The Expression of Mouse Gene P1A in Testis Does Not Prevent Safe Induction of Cytolytic T Cells Against a P1A-Encoded Tumor Antigen,”Int. J. Cancer1997; 70:349-356.
Van Den Eynde, B. et al., “Presence on a Human Melanoma of Multiple Antigens Recognized by Autologous CTL,”Int. J. Cancer1989; 44:634-640.
Van Der Bruggen, Pierre et al., “Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw 1601,”Eur. J. Immunol.1994; 24:2134-2140.
Van Der Bruggen, P. et al., “A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma,”ScienceDec. 13, 1991; 254:1643-1647.
Van Den Eynde, Benoit J. et al., “T cell defined tumor antigens,”Current Opinion in Immunology1997; 9:684-693.

Affiliated with

Also associated with

Rating

Tumor rejection antigens does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor rejection antigens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor rejection antigens will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4143959